LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday that ViiV Healthcare's FLAIR study met its primary endpoint, reporting "positive headline results".
ViiV is a specialist HIV joint venture, majority owned by Glaxo, with Pfizer Inc and Shionogi Ltd as shareholders.
FLAIR - or first long-acting injectable regimen - is the study of a long-acting, injectable two-drug regimen for the treatment of HIV.
The study showed that long-acting cabotegravir and rilpivirine, injected once a month, reported a similar efficacy to the daily three drug regimen Triumeq.
John Pottage, chief scientific and medical officer of ViiV, said: "The FLAIR data provide further evidence that a long-acting, injectable 2DR of cabotegravir and rilpivirine may offer an alternative to daily, oral therapy for people who have previously achieved viral suppression.
"This innovative dosing regimen could transform HIV therapy by reducing the number of days a person receives treatment from 365 to 12."
Shares in Glaxo were trading down 0.7% at 1,519.80 pence on Tuesday afternoon.
Glaxosmithkline (GSK)